Compare Immunovant Inc. Common Stock (IMVT) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs LyondellBasell Industries NV — how do they compare? Immunovant Inc. Common Stock trades at $30.3 (market cap $6.25B), while LyondellBasell Industries NV trades at $60.46 (market cap $19.49B). The key difference: LyondellBasell Industries NV is far larger — about 3.1× Immunovant Inc. Common Stock's market cap, and LyondellBasell Industries NV pays a 4.57% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and LyondellBasell Industries NV for 87 Days on average.
| IMVT | LYB | |
|---|---|---|
Market Cap | $6.25B | $19.49B |
Volume | 1,755,411 | 6,033,396 |
Sector | Health | Basic Materials |
52-Week High | $44.96 | $82.38 |
52-Week Low | $17.03 | $42.28 |
Typical Hold Time | 0 Days | 87 Days |
Enterprise Value | $5.35B | $31.08B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LyondellBasell (LYB) trades at $58.49, down 0.75% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings show volatility, with a Q2 2026 beat but a net loss for 2025. Revenue has declined from $50.5B in 2022 to $30.2B in 2025, though 2026 projects a slight recovery. The stock offers a dividend, but news highlights concerns over dividend sustainability amid sector challenges.
Outlook is cautious; analyst consensus is split with a $69.38 price target suggesting upside, but profitability metrics are weak. Key risks include persistent negative margins, high debt, and chemical sector cyclicality. Investment opportunity hinges on operational turnaround and market recovery, but near-term headwinds prevail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
